pharmaceutical investing Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series
Cesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series Products That Provide Automated, Closed System Cellular Processing
Cesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
